NANO MRNA Co.,Ltd. — Investor Relations & Filings
NANO MRNA Co., Ltd. is a biotechnology firm that operates as a platform company and an IP Generator specializing in mRNA-based medicine. The company focuses on creating and out-licensing intellectual property for novel therapeutics by connecting drug discovery seeds with medical and development needs. It leverages a proprietary drug delivery system (DDS) based on micellar nanoparticle technology to advance its pipeline. Key clinical programs include an mRNA therapy for osteoarthritis (RUNX1 mRNA) and an antisense oligonucleotide (ASO) for glioblastoma (TUG1 ASO). Evolving from its predecessor, NanoCarrier, the company combines a legacy of R&D in nanoparticle technology with a strategic focus on RNA drug discovery. It also co-developed and markets Comlex®, an antibacterial agent for ear, nose, and throat conditions.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 取締役の報酬額改定および譲渡制限付株式報酬制度の改定に関するお知らせ | 2026-05-22 | Japanese | |
| 2026年3月期決算説明会資料 | 2026-05-19 | Japanese | |
| 第22回新株予約権（行使価額修正条項付）の月間行使状況に関するお知らせ | 2026-05-01 | Japanese | |
| （訂正）「戦略子会社NANO MRNAによるLuna RD株式会社の株式取得（子会社化）による子会社の異動に関するお知らせ」の一部訂正について | 2026-04-24 | Japanese | |
| 戦略子会社NANO MRNAによるLuna RD株式会社の株式取得（子会社化）による子会社の異動に関するお知らせ | 2026-04-24 | Japanese | |
| 確認書 | 2025-11-14 | Japanese |
Browse filings by year
12 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
5 filings
| |||||
| 46779360 | 取締役の報酬額改定および譲渡制限付株式報酬制度の改定に関するお知らせ | 2026-05-22 | Japanese | ||
| 46541742 | 2026年3月期決算説明会資料 | 2026-05-19 | Japanese | ||
| 46880444 | 第22回新株予約権（行使価額修正条項付）の月間行使状況に関するお知らせ | 2026-05-01 | Japanese | ||
| 46878698 | （訂正）「戦略子会社NANO MRNAによるLuna RD株式会社の株式取得（子会社化）による子会社の異動に関するお知らせ」の一部訂正について | 2026-04-24 | Japanese | ||
| 46878902 | 戦略子会社NANO MRNAによるLuna RD株式会社の株式取得（子会社化）による子会社の異動に関するお知らせ | 2026-04-24 | Japanese | ||
|
2025
10 filings
| |||||
| 8318115 | 確認書 | 2025-11-14 | Japanese | ||
| 8318053 | 半期報告書－第30期(2025/04/01－2026/03/31) | 2025-11-14 | Japanese | ||
| 8024747 | 訂正有価証券届出書（参照方式） | 2025-10-15 | Japanese | ||
| 7978489 | 有価証券届出書（参照方式） | 2025-10-08 | Japanese | ||
| 7239401 | 臨時報告書 | 2025-07-18 | Japanese | ||
| 7242184 | 臨時報告書 | 2025-07-01 | Japanese | ||
| 7243776 | 内部統制報告書－第29期(2024/04/01－2025/03/31) | 2025-06-30 | Japanese | ||
| 7243737 | 確認書 | 2025-06-30 | Japanese | ||
| 7243707 | 有価証券報告書－第29期(2024/04/01－2025/03/31) | 2025-06-30 | Japanese | ||
| 7263945 | 臨時報告書 | 2025-05-14 | Japanese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Alpha Tau Medical Ltd.
Clinical-stage oncology firm developing alpha radiation the…
|
DRTS | US | Professional, scientific and te… |
|
Alteogen Inc.
Biopharmaceutical firm developing biologics with proprietar…
|
196170 | KR | Professional, scientific and te… |
|
ALTERITY THERAPEUTICS LIMITED
Clinical-stage developer of disease-modifying therapies for…
|
ATH | AU | Professional, scientific and te… |
|
AlzeCure Pharma
Develops therapies for severe diseases, focusing on Alzheim…
|
ALZCUR | SE | Professional, scientific and te… |
|
AMPLIA THERAPEUTICS LIMITED
Clinical-stage developer of FAK inhibitors for solid tumors…
|
ATX | AU | Professional, scientific and te… |
|
ANAPTYSBIO, INC
Clinical-stage biotech developing immunology therapeutics f…
|
ANAB | US | Professional, scientific and te… |
|
ANATARA LIFESCIENCES LTD
Develops non-antibiotic gastrointestinal health solutions f…
|
ANR | AU | Professional, scientific and te… |
|
AngioLab, Inc.
Develops angiogenesis inhibitors for pharmaceuticals and he…
|
251280 | KR | Professional, scientific and te… |
|
Anhui Wanbang Pharmaceutical Technology Co.,Ltd.
Pharmaceutical CRO specializing in clinical trials, BE stud…
|
301520 | CN | Professional, scientific and te… |
|
Anixa Biosciences Inc
A clinical-stage biotech developing therapies and vaccines …
|
ANIX | US | Professional, scientific and te… |
NANO MRNA Co.,Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/13521/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=13521 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=13521 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=13521 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 13521}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for NANO MRNA Co.,Ltd. (id: 13521)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.